Back to search
Localized Non-Resectable Adult Liver Carcinoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Localized Non-Resectable Adult Liver Carcinoma trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Localized Non-Resectable Adult Liver Carcinoma trials you may qualify forThis early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (w…
Surgery is the main curative treatment for hepatocellular carcinoma(HCC) patients, but 70%-80% of HCC patients are in the middle and advanced stages at the time…
This pilot clinical trial studies stereotactic body radiation therapy in treating patients with liver cancer that cannot be removed by surgery. Stereotactic rad…
TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) may stop the growth of tumor cells by allowing the immune system to…
Primary liver tumors, with hepatocellular carcinoma (HCC) accounting for 80%, represent 6% of global cancer incidence and 9% of global cancer-associated mortali…